CN108350068A - 使用抗-il-17a/f抗体的治疗方法 - Google Patents

使用抗-il-17a/f抗体的治疗方法 Download PDF

Info

Publication number
CN108350068A
CN108350068A CN201680062741.XA CN201680062741A CN108350068A CN 108350068 A CN108350068 A CN 108350068A CN 201680062741 A CN201680062741 A CN 201680062741A CN 108350068 A CN108350068 A CN 108350068A
Authority
CN
China
Prior art keywords
antibody
human
seq
people
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680062741.XA
Other languages
English (en)
Chinese (zh)
Inventor
S·格拉特
L·伊欧奈斯库
M·琼斯
R·奥利弗
S·G·肖
F·斯特里麦诺普洛
V·P·K·瓦佳赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57223670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108350068(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Priority to CN202211252125.4A priority Critical patent/CN116059350A/zh
Publication of CN108350068A publication Critical patent/CN108350068A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680062741.XA 2015-10-27 2016-10-26 使用抗-il-17a/f抗体的治疗方法 Pending CN108350068A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211252125.4A CN116059350A (zh) 2015-10-27 2016-10-26 使用抗-il-17a/f抗体的治疗方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562246989P 2015-10-27 2015-10-27
US62/246,989 2015-10-27
US201662303230P 2016-03-03 2016-03-03
US62/303,230 2016-03-03
US201662346826P 2016-06-07 2016-06-07
US62/346,826 2016-06-07
US201662405546P 2016-10-07 2016-10-07
US62/405,546 2016-10-07
PCT/EP2016/075821 WO2017072183A1 (en) 2015-10-27 2016-10-26 Methods of treatment using anti-il-17a/f antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211252125.4A Division CN116059350A (zh) 2015-10-27 2016-10-26 使用抗-il-17a/f抗体的治疗方法

Publications (1)

Publication Number Publication Date
CN108350068A true CN108350068A (zh) 2018-07-31

Family

ID=57223670

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680062741.XA Pending CN108350068A (zh) 2015-10-27 2016-10-26 使用抗-il-17a/f抗体的治疗方法
CN202211252125.4A Pending CN116059350A (zh) 2015-10-27 2016-10-26 使用抗-il-17a/f抗体的治疗方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211252125.4A Pending CN116059350A (zh) 2015-10-27 2016-10-26 使用抗-il-17a/f抗体的治疗方法

Country Status (16)

Country Link
US (3) US11492396B2 (enExample)
EP (1) EP3368570A1 (enExample)
JP (5) JP6931648B2 (enExample)
KR (2) KR20240156437A (enExample)
CN (2) CN108350068A (enExample)
AU (2) AU2016347471B2 (enExample)
BR (1) BR112018008075A2 (enExample)
CA (1) CA3001260A1 (enExample)
CL (3) CL2018001135A1 (enExample)
CO (1) CO2018004493A2 (enExample)
IL (1) IL258515A (enExample)
MX (4) MX2018005031A (enExample)
MY (3) MY206805A (enExample)
RU (1) RU2754683C2 (enExample)
SG (2) SG10202112586WA (enExample)
WO (1) WO2017072183A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
IL297689A (en) * 2020-04-30 2022-12-01 Janssen Pharmaceutica Nv Methods of identifying modulators of the il-17 pathway
EP4471427A1 (en) * 2023-05-31 2024-12-04 Centre Hospitalier Universitaire De Nice Biomarker for spondyloarthitis diagnostic and response to treatment

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
CN101589061A (zh) * 2006-10-18 2009-11-25 Ucb医药有限公司 结合il-17a和il-17f的抗体分子
CN103360493A (zh) * 2008-08-29 2013-10-23 霍夫曼-拉罗奇有限公司 交叉反应性和双特异性抗-il-17a/f抗体
CN103384682A (zh) * 2011-01-14 2013-11-06 Ucb医药有限公司 结合il-17a和il-17f的抗体分子
CN103717618A (zh) * 2011-05-05 2014-04-09 默克专利股份有限公司 抗il-17a，il-17f和/或il17-a/f的氨基酸序列以及包含其的多肽
CN102083858B (zh) * 2008-05-05 2015-01-14 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
EP2294083B1 (en) * 2008-04-23 2015-07-29 UCB Biopharma SPRL Epitopes of il-17a and il-17f and antibodies specific thereto

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
EP1231268B1 (en) 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
PT1570267E (pt) 2002-12-03 2012-01-03 Ucb Pharma Sa Ensaio para a identificação de células produtoras de anticorpos
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US7622116B2 (en) 2006-02-10 2009-11-24 Zymogenetics, Inc. Method of treating inflammation using soluble IL-17RCX4
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
PT2334705T (pt) 2008-09-26 2017-03-22 Ucb Biopharma Sprl Produtos biológicos
RU2394575C1 (ru) * 2009-04-13 2010-07-20 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ лечения псориаза
CA2759848C (en) 2009-05-05 2018-12-04 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
AU2012341081B2 (en) 2011-11-21 2015-06-04 Novartis Ag Methods of treating psoriatic arthritis (PsA) using IL-17 antagonists and PsA response or non- response alleles
EP2838560A2 (en) 2012-04-20 2015-02-25 Novartis AG Methods of treating ankylosing spondylitis using il-17 antagonists
GB201213571D0 (en) 2012-07-31 2012-09-12 Univ Leuven Kath Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
HRP20192076T1 (hr) * 2013-02-08 2020-02-07 Novartis Ag Anti-il-17a protutijela i njihova uporaba u liječenju autoimunih i upalnih poremećaja
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
KR20230170796A (ko) 2014-09-10 2023-12-19 노파르티스 아게 건선성 관절염 환자에서 구조적 손상의 진행을 억제하기 위한 il-17 길항제의 용도
JP6858766B2 (ja) 2015-10-19 2021-04-14 ノバルティス アーゲー インターロイキン１７（ｉｌ−１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
GB201522391D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibody molecules
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007106769A2 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
CN101589061A (zh) * 2006-10-18 2009-11-25 Ucb医药有限公司 结合il-17a和il-17f的抗体分子
EP2294083B1 (en) * 2008-04-23 2015-07-29 UCB Biopharma SPRL Epitopes of il-17a and il-17f and antibodies specific thereto
CN102083858B (zh) * 2008-05-05 2015-01-14 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
CN103360493A (zh) * 2008-08-29 2013-10-23 霍夫曼-拉罗奇有限公司 交叉反应性和双特异性抗-il-17a/f抗体
CN103384682A (zh) * 2011-01-14 2013-11-06 Ucb医药有限公司 结合il-17a和il-17f的抗体分子
CN103717618A (zh) * 2011-05-05 2014-04-09 默克专利股份有限公司 抗il-17a，il-17f和/或il17-a/f的氨基酸序列以及包含其的多肽

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022127842A1 (zh) * 2020-12-17 2022-06-23 上海华奥泰生物药业股份有限公司 靶向il-17a和il-36r的双特异性抗体及其应用

Also Published As

Publication number Publication date
RU2754683C2 (ru) 2021-09-06
CL2018001135A1 (es) 2019-05-10
JP2018535961A (ja) 2018-12-06
RU2018118029A (ru) 2019-12-04
SG11201802887PA (en) 2018-05-30
US11492396B2 (en) 2022-11-08
US20190292255A1 (en) 2019-09-26
KR20240156437A (ko) 2024-10-29
CL2021002815A1 (es) 2022-07-29
IL258515A (en) 2018-05-31
MX2018005031A (es) 2018-06-13
JP6931750B2 (ja) 2021-09-08
JP2021119168A (ja) 2021-08-12
US20230279093A1 (en) 2023-09-07
JP2023025019A (ja) 2023-02-21
RU2018118029A3 (enExample) 2020-09-17
MX2022009379A (es) 2022-09-07
MY196489A (en) 2023-04-17
BR112018008075A2 (pt) 2018-12-04
SG10202112586WA (en) 2021-12-30
CO2018004493A2 (es) 2018-11-30
WO2017072183A1 (en) 2017-05-04
JP2021130707A (ja) 2021-09-09
CA3001260A1 (en) 2017-05-04
MY206805A (en) 2025-01-08
JP6931648B2 (ja) 2021-09-08
JP2025037926A (ja) 2025-03-18
MY207225A (en) 2025-02-06
EP3368570A1 (en) 2018-09-05
CN116059350A (zh) 2023-05-05
AU2023255037A1 (en) 2023-11-16
AU2016347471A1 (en) 2018-05-10
KR20180067676A (ko) 2018-06-20
MX2023004315A (es) 2023-05-08
MX2022009380A (es) 2022-09-07
AU2016347471B2 (en) 2023-08-03
US20230287100A1 (en) 2023-09-14
JP7176044B2 (ja) 2022-11-21
CL2021002816A1 (es) 2022-07-29

Similar Documents

Publication Publication Date Title
DK2663577T3 (en) Antibody that binds to IL-17A and IL-17F
AU2016347471B2 (en) Methods of treatment using anti-IL-17A/F antibodies
JP5782385B2 (ja) ヒトｏｘ４０に対する特異性を有する抗体分子
US9873735B2 (en) Method of treatment with antibodies having specificity for human OX40
RU2746926C2 (ru) Антагонистические антитела, которые связываются с человеческими TGFβ1, TGFβ2 и TGFβ3, и их применение при лечении фиброза легких
TWI476004B (zh) 對人類ｉｌ－１３具結合專一性的抗體分子
CN101861336A (zh) 人gm-csf抗原结合蛋白质
TW201412774A (zh) 能結合胸腺基質淋巴細胞生成素之抗原結合蛋白
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
HK1187929A (en) Antibody molecules which bind il-17a and il-17f

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Brussels

Applicant after: UCB biopharmaceutical Co., Ltd

Address before: Brussels

Applicant before: UCB BIOPHARMA SPRL